YUTIQ Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Yutiq, and when can generic versions of Yutiq launch?
Yutiq is a drug marketed by Eyepoint Pharms and is included in one NDA. There is one patent protecting this drug.
This drug has one hundred and seventy-six patent family members in twenty-seven countries.
The generic ingredient in YUTIQ is fluocinolone acetonide. There are twelve drug master file entries for this compound. Nineteen suppliers are listed for this compound. Additional details are available on the fluocinolone acetonide profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Yutiq
A generic version of YUTIQ was approved as fluocinolone acetonide by TARO on April 27th, 1982.
Summary for YUTIQ
| International Patents: | 176 |
| US Patents: | 1 |
| Applicants: | 1 |
| NDAs: | 1 |
| Formulation / Manufacturing: | see details |
| Drug Prices: | Drug price information for YUTIQ |
| What excipients (inactive ingredients) are in YUTIQ? | YUTIQ excipients list |
| DailyMed Link: | YUTIQ at DailyMed |
Anatomical Therapeutic Chemical (ATC) Classes for YUTIQ
US Patents and Regulatory Information for YUTIQ
YUTIQ is protected by one US patents.
Patents protecting YUTIQ
Injectable sustained release delivery devices
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Eyepoint Pharms | YUTIQ | fluocinolone acetonide | IMPLANT;INTRAVITREAL | 210331-001 | Oct 12, 2018 | RX | Yes | Yes | See Plans and Pricing | See Plans and Pricing | Y | See Plans and Pricing | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for YUTIQ
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Eyepoint Pharms | YUTIQ | fluocinolone acetonide | IMPLANT;INTRAVITREAL | 210331-001 | Oct 12, 2018 | See Plans and Pricing | See Plans and Pricing |
| Eyepoint Pharms | YUTIQ | fluocinolone acetonide | IMPLANT;INTRAVITREAL | 210331-001 | Oct 12, 2018 | See Plans and Pricing | See Plans and Pricing |
| Eyepoint Pharms | YUTIQ | fluocinolone acetonide | IMPLANT;INTRAVITREAL | 210331-001 | Oct 12, 2018 | See Plans and Pricing | See Plans and Pricing |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for YUTIQ
See the table below for patents covering YUTIQ around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| European Patent Office | 1162978 | See Plans and Pricing | |
| Portugal | 2233112 | See Plans and Pricing | |
| Taiwan | 201422269 | Injectable sustained release delivery devices and method for their manufacturing | See Plans and Pricing |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for YUTIQ
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 2233112 | 132014902285293 | Italy | See Plans and Pricing | PRODUCT NAME: FLUOCINOLONE ACETONIDE(ILUVIEN); AUTHORISATION NUMBER(S) AND DATE(S): 042616019, 20140530;PL27813/0001, 20120504 |
| 2233112 | 122014000063 | Germany | See Plans and Pricing | PRODUCT NAME: FLUOCINOLONACETONID; NAT. REGISTRATION NO/DATE: 82809.00.00 20120720; FIRST REGISTRATION: GB PL 27813/0001 20120504 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Make Better Decisions: Try a trial or see plans & pricing
Serving leading biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2022 - 2023
NCE-1 Patent Challenge Dates 2022 - 2023
ClinicalTrialExchange - Connecting volunteers and trials
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2022, www.DrugPatentWatch.com.
Follow DrugPatentWatch:
